Poor sleep quality is very common among patients with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS), and is associated with a lower quality of life, and greater ... Read more
Multiple sclerosis (MS) patients may experience severe disease exacerbation after switching from Novartis’ Gilenya (fingolimod) to Sanofi Genzyme’s Lemtrada (alemtuzumab), a case report suggests. This unexpected high disease activity raises questions about ... Read more
The newest kids on the MS block, disease-modifying therapies (DMT) such as Genentech’s Ocrevus (ocrelizumab) and Sanofi Genzyme’s Lemtrada (alemtuzumab), are attracting a lot of interest these days. But, ... Read more
An increase in multiple sclerosis cases in the Middle East and North Africa has prompted Bayer to introduce to the region an injector that patients can use to treat themselves.
Researchers have suggested that ... Read more
Most multiple sclerosis patients who try Bayer’s BETACONNECT auto-injector stick with their treatment, a study reports.
The electronic product may overcome the problem of many patients failing to stick to a therapy ... Read more
The U.S. Food and Drug Administration has approved a supplemental biologics license application for two Bayer products that help multiple sclerosis patients keep track of their injections of Betaseron (interferon beta-1b). The products ... Read more
Multiple sclerosis (MS) patients who experienced a relapse between their first and second rounds of Lemtrada (alemtuzumab) had good treatment outcomes over the long run, according to a Phase ... Read more
The U.S. Food and Drug Administration (FDA) has accepted Bayer’s filing of a supplemental biologics license application (sBLA) for two products designed to improve the lives of people with multiple ... Read more
Global pharma Bayer Healthcare aims to improve human health by diagnosing, preventing, and treating a variety of diseases. The company currently provides products for general medicine, hematology, neurology, oncology, and women’s healthcare. ... Read more
Bayer HealthCare is pleased to announce the US Food and Drug Administration (FDA) has granted the approval of BETACONNECT, a first-of-its-kind electronic autoinjector indicated as a treatment for relapsing-remitting multiple sclerosis ... Read more
Results from the BENEFIT11 trial indicate that early treatment with IFNB-1b leads to improvements in cognition and fatigue in the long-term, as well as sustained employment and favorable magnetic resonance imaging ... Read more
Bayer HealthCare recently announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a supplemental Biologics License Application (sBLA) for BETACONNECT for the treatment of relapsing-remitting multiple ... Read more